Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

6.010 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.010
Bid (Size) 5.620 (10)
Ask (Size) 6.830 (1)
Prev. Close 6.010
Today's Range 6.010 - 6.010
52wk Range 4.440 - 11.80
Shares Outstanding 19,495,683
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
From Nuvectis Pharma, Inc.
Via GlobeNewswire

Performance

YTD
+11.5%
+11.5%
1 Month
+0.2%
+0.2%
3 Month
-22.3%
-22.3%
6 Month
-45.2%
-45.2%
1 Year
-29.3%
-29.3%

More News

Read More
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis (NVCT) Q2 Loss Widens 43%
Via The Motley Fool
Discover the top movers in Thursday's pre-market session.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
Via News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?
Via News Direct
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
From Market News Alerts
Via Business Wire
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
From Market News Alerts
Via Business Wire
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Via Benzinga

Frequently Asked Questions

Is Nuvectis Pharma, Inc. - Common Stock publicly traded?
Yes, Nuvectis Pharma, Inc. - Common Stock is publicly traded.
What exchange does Nuvectis Pharma, Inc. - Common Stock trade on?
Nuvectis Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nuvectis Pharma, Inc. - Common Stock?
The ticker symbol for Nuvectis Pharma, Inc. - Common Stock is NVCT on the Nasdaq Stock Market
What is the current price of Nuvectis Pharma, Inc. - Common Stock?
The current price of Nuvectis Pharma, Inc. - Common Stock is 6.010
When was Nuvectis Pharma, Inc. - Common Stock last traded?
The last trade of Nuvectis Pharma, Inc. - Common Stock was at 10/23/25 04:00 PM ET
What is the market capitalization of Nuvectis Pharma, Inc. - Common Stock?
The market capitalization of Nuvectis Pharma, Inc. - Common Stock is 117.17M
How many shares of Nuvectis Pharma, Inc. - Common Stock are outstanding?
Nuvectis Pharma, Inc. - Common Stock has 117M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.